Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $81.29 Consensus Target Price from Analysts

Structure Therapeutics Inc. (NASDAQ:GPCR) has received an average rating of “Buy” from the eight analysts that are covering the firm, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $81.29.

A number of research analysts recently commented on GPCR shares. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price target on shares of Structure Therapeutics in a research note on Thursday, December 19th. JMP Securities reaffirmed a “market outperform” rating and set a $91.00 price target on shares of Structure Therapeutics in a report on Wednesday, December 18th. Finally, Stifel Nicolaus started coverage on shares of Structure Therapeutics in a research note on Wednesday, January 8th. They issued a “buy” rating and a $50.00 price objective on the stock.

Institutional Trading of Structure Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of GPCR. Bank of Montreal Can bought a new position in shares of Structure Therapeutics during the second quarter worth about $1,064,000. JPMorgan Chase & Co. raised its holdings in Structure Therapeutics by 302.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 33,936 shares of the company’s stock worth $1,489,000 after purchasing an additional 25,500 shares during the last quarter. Vestal Point Capital LP lifted its position in shares of Structure Therapeutics by 105.4% in the 3rd quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company’s stock worth $50,474,000 after purchasing an additional 590,000 shares during the period. abrdn plc boosted its stake in shares of Structure Therapeutics by 132.7% in the 3rd quarter. abrdn plc now owns 217,083 shares of the company’s stock valued at $9,528,000 after purchasing an additional 123,789 shares during the last quarter. Finally, Barclays PLC increased its position in shares of Structure Therapeutics by 64.5% during the third quarter. Barclays PLC now owns 81,138 shares of the company’s stock worth $3,562,000 after buying an additional 31,815 shares during the period. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Price Performance

Structure Therapeutics stock opened at $27.40 on Monday. The firm has a market cap of $1.57 billion, a PE ratio of -37.03 and a beta of -2.75. The stock’s fifty day moving average price is $29.21 and its two-hundred day moving average price is $34.92. Structure Therapeutics has a one year low of $23.50 and a one year high of $62.74.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.